Indian Biotech Firm Panacea Biotec On Schedule To Produce COVID-19 Vaccine

India’s Bharat Biotech and Zydus Cadila, listed as Cadila Healthcare, have received regulatory approvals to test their vaccine candidates in humans.

covid19

Indian biotech firm Panacea Biotec has said that it is on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021. Last month, the company had announced that it would partner with US-based Refana Inc to make a potential coronavirus vaccine, in a collaboration that expects to have over 40 million doses available early next year.

“We continue to evaluate candidate vaccines in pre-clinical investigations in accordance with (our) timeline. We do not envisage the commencement of clinical studies until September this year,” the company was quoted as saying.

The company has set production targets of 500 million doses for the year 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate.

The company is looking to produce an inactivated COVID-19 vaccine, the technology for which is well known and has been used to make vaccines against diseases such as influenza and measles.

India’s Bharat Biotech and Zydus Cadila, listed as Cadila Healthcare, have received regulatory approvals to test their vaccine candidates in humans.

Meanwhile, India saw yet another record single-day jump of 26,506 COVID-19 cases pushing its tally to 7,93,802 on Friday, while the death toll climbed to 21,604 with 475 people succumbing to the infection, according to the Union Health Ministry data.

The number of tests for detection of COVID-19 has crossed the 11-million mark. According to ICMR, a cumulative total of 1,10,24,491 samples have been tested up to July 9 with 2,83,659 samples being tested on Thursday.

The number of recoveries stands at 4,95,512 while there are 2,76,685 active cases of coronavirus infection presently in the country, the updated data at 8 am showed.

“Thus, around 62.42 per cent of patients have recovered so far,” an official said.

Facebook Comments